@article{739bebc585b34c729b4400cba2e32bd4,
title = "From a deep learning model back to the brain—Identifying regional predictors and their relation to aging",
abstract = "We present a Deep Learning framework for the prediction of chronological age from structural magnetic resonance imaging scans. Previous findings associate increased brain age with neurodegenerative diseases and higher mortality rates. However, the importance of brain age prediction goes beyond serving as biomarkers for neurological disorders. Specifically, utilizing convolutional neural network (CNN) analysis to identify brain regions contributing to the prediction can shed light on the complex multivariate process of brain aging. Previous work examined methods to attribute pixel/voxel-wise contributions to the prediction in a single image, resulting in “explanation maps” that were found noisy and unreliable. To address this problem, we developed an inference scheme for combining these maps across subjects, thus creating a population-based, rather than a subject-specific map. We applied this method to a CNN ensemble trained on predicting subjects' age from raw T1 brain images in a lifespan sample of 10,176 subjects. Evaluating the model on an untouched test set resulted in mean absolute error of 3.07 years and a correlation between chronological and predicted age of r = 0.98. Using the inference method, we revealed that cavities containing cerebrospinal fluid, previously found as general atrophy markers, had the highest contribution for age prediction. Comparing maps derived from different models within the ensemble allowed to assess differences and similarities in brain regions utilized by the model. We showed that this method substantially increased the replicability of explanation maps, converged with results from voxel-based morphometry age studies and highlighted brain regions whose volumetric variability correlated the most with the prediction error.",
keywords = "brain aging, convolutional neural networks, deep learning, interpretability, neuroimaging",
author = "Gidon Levakov and Gideon Rosenthal and Ilan Shelef and Raviv, {Tammy Riklin} and Galia Avidan",
note = "Funding Information: Data used in preparation of this article were partially obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL) funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO). As such, the investigators within ADNI and AIBL contributed to the design and implementation of ADNI and AIBL and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI and AIBL investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf and at www.aibl.csiro.au . Funding Information: This research was supported by an Internal funding grant for interdisciplinary research in Ben Gurion University of the Negev to GA and IS. Our project would not have been possible without several open databases and groups that invested considerable resource and efforts to support neuroimaging data sharing. We wish to acknowledge those study groups and funding agencies: —Data were provided in part by the Consortium for Reliability and Reproducibility ( http://fcon_1000.projects.nitrc.org/indi/CoRR/html/index.html ). —Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. —Data were provided in part by the Brain Genomics Superstruct Project of Harvard University and the Massachusetts General Hospital, (Principal Investigators: Randy Buckner, Joshua Roffman, and Jordan Smoller), with support from the Center for Brain Science Neuroinformatics Research Group, the Athinoula A. Martinos Center for Biomedical Imaging, and the Center for Human Genetic Research. Twenty individual investigators at Harvard and MGH generously contributed data to GSP. —Data were provided in part by the Functional Connectomes Project ( https://www.nitrc.org/projects/fcon_1000/ ). —Primary support for the work by Adriana Di Martino, and Michael P. Milham and his team was provided by the NIMH (K23MH087770), the Leon Levy Foundation, Joseph P. Healy and the Stavros Niarchos Foundation to the Child Mind Institute, NIMH award to MPM (R03MH096321), National Institute of Mental Health (NIMH 5R21MH107045), Nathan S. Kline Institute of Psychiatric Research), Phyllis Green and Randolph Cowen to the Child Mind Institute. —Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database ( www.ppmi-info.org/data ). For up‐to‐date information on the study, visit www.ppmi-info.org . PPMI—a public‐private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including [list of the full names of all of the PPMI funding partners can be found at www.ppmi-info.org/fundingpartners ]. —Data used in the preparation of this work were obtained from the International Consortium for Brain Mapping (ICBM) database ( www.loni.usc.edu/ICBM ). The ICBM project (Principal Investigator John Mazziotta, M.D., University of California, Los Angeles) is supported by the National Institute of Biomedical Imaging and BioEngineering. ICBM is the result of efforts of co‐investigators from UCLA, Montreal Neurologic Institute, University of Texas at San Antonio, and the Institute of Medicine, Juelich/Heinrich Heine University—Germany. —Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of aging (AIBL) funded by the Commonwealth Scientific and Industrial Research Organization (CSIRO) which was made available at the ADNI database ( www.loni.usc.edu/ADNI ). The AIBL researchers contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at www.aibl.csiro.au . —Data were provided by the Southwest University Longitudinal Imaging Multimodal (SLIM) Brain Data Repository ( http://fcon_1000.projects.nitrc.org/indi/retro/southwestuni_qiu_index.html ). —Data were provided in part by the IXI database ( http://brain-development.org/ ). —OASIS is made available by Dr. Randy Buckner at the Howard Hughes Medical Institute (HHMI) at Harvard University, the Neuroinformatics Research Group ( NRG ) at Washington University School of Medicine, and the Biomedical Informatics Research Network ( BIRN ). Support for the acquisition of this data and for data analysis was provided by NIH grants P50 AG05681, P01 AG03991, P20 MH071616, RR14075, RR 16594, U24 RR21382, the Alzheimer's Association, the James S. McDonnell Foundation, the Mental Illness and Neuroscience Discovery Institute, and HHMI. —Data used in the preparation of this article were obtained from the Consortium for Neuropsychiatric Phenomics (NIH Roadmap for Medical Research grants UL1‐DE019580, RL1MH083268, RL1MH083269, RL1DA024853, RL1MH083270, RL1LM009833, PL1MH083271, and PL1NS062410). This data was obtained from the OpenfMRI database. Its accession number is ds000030. —Data were provided by the Center for Biomedical Research Excellence (COBRE) ( http://fcon_1000.projects.nitrc.org/indi/retro/cobre.html ). —Data were provided in part by the Child and Adolescent NeuroDevelopment Initiative (CANDI; Kennedy et al., 2012 )—Schizophrenia Bulletin 2008 project. —Data were provided in part by the Brainomics project ( http://brainomics.cea.fr/ ). —Data used in this manuscript was partially accessed through the Neuroimaging Informatics Tools and Resources Clearinghouse. NITRC is funded by the NIH Grant numbers: 2R44NS074540 and 1U24EB023398a. —Data used in this manuscript was partially accessed through the LONI Image and Data Archive. IDA is funded by the NIH and the NIBIB grant numbers P41EB015922 U54EB020406. CORR ADNI GSP FCP ABIDE PPMI ICBM AIBL SLIM IXI OASIS CNP COBRE CANDI Brainomics NITRC IDA Funding Information: Ben Gurion University of the Negev, Grant/Award Number: Internal funding grant Funding information Publisher Copyright: {\textcopyright} 2020 The Authors. Human Brain Mapping published by Wiley Periodicals, Inc.",
year = "2020",
month = aug,
day = "15",
doi = "10.1002/hbm.25011",
language = "English",
volume = "41",
pages = "3235--3252",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "12",
}